Epizyme, Inc. vs GlaxoSmithKline LLC

Judgment - Granting Request for Adverse Judgment After Institution of Trial

Ex. 3001

Patent Owner's Request for Adverse Judgment

Statutory Disclaimer of USP 9562041

Petitioner's Third Updated Mandatory Notices

Petitioner's Updated Power of Attorney

Petitioner's Second Updated Mandatory Notices

Patent Owner¿¿¿s Opposition to Petitioner¿¿¿s Motion to Stay Reissue Application

Granting Petitioners Motion for Pro Hac Vice Admission of Charles T. Steenburg 37 C.F.R. sec 42.10

Petitioner's Motion to Stay Reissue Application

File History of Reissue Application 16/872,986 (as of July 7, 2020)

Order Conduct of the Proceeding

Declaration of Charles T. Steenburg in Support of Motion for Admission Pro Hac Vice

Petitioner's Unopposed Motion for Pro Hac Vice Admission of Charles T. Steenburg

Patent Owner's Updated Mandatory Notices

Petitioner's First Updated Mandatory Notices

Trial Instituted Document

SCHEDULING ORDER

Patent Owner's Updated Mandatory Notices

Patent Owner's Power of Attorney

Patent Owner Mandatory Notices

Patent Owner Power of Attorney

Mandatory Notice IPR2020-00327

POA IPR2020-00327

Notice of Accord Filing Date

File History for U.S. Patent No. 9,562,041 ("the `041 FH") (part 1)

Power of Attorney

U.S. Patent No. 9,562,041 ("the `041 patent")

U.S. Patent No. 9,956,210 ("the `210 patent")

U.S. Provisional App. No. 61/647,713 ("GSK's Provisional")

PCT Patent App. No. US2013/041115

File History for U.S. Patent No. 9,956,210 ("the `210 FH")

U.S. Patent No. 8,410,088 ("Kuntz")

Communication regarding entity status for U.S. Provisional App. No. 61/499,595

U.S. Patent App. No. 13/447,007 ("Kuntz Application") (part 1)

U.S. Patent App. No. 13/447,007 ("Kuntz Application") (part 2)

Assignment information for U.S. Patent App. No. 13/447,007 ("Kuntz Assignment")

Declaration of Jonathan L. Sessler ("Sessler")

File History for U.S. Patent No. 9,562,041 ("the `041 FH") (part 2)

U.S. Provisional App. No. 61/499,595 ("Kuntz's Provisional")

Verma, et al., Recent progress in the discovery of small-molecule inhibitors of the HMT EZH2 for the treatment of cancer (2013)

Knutson, et al., A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells (2012)

Wu, et al., Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations (2013)

Kalinic, et al., Structural insights into binding of small molecule inhibitors to enhancer of zeste homolog 2 (2014)

McCabe, et al., Mutation of A677 in histonemethyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) (2012)

Yang, et al., Structure-activity relationship studies for Enhancer of Zeste Homologue 2 (EZH2) and EZH1 inhibitors (2016)

Curriculum Vitae of Jonathan L. Sessler ("Sessler CV")

Declaration of Izidore Lossos ("Lossos")

Curriculum Vitae of Izidore Lossos ("Lossos CV")

Verma, et al., Identification of potent, selective cell-active inhibitors of the histone lysine methyltransferase EZH2 (2012)

Ciferri, et al., Molecular architecture of human polycomb repressive complex 2 (2012)

Jiao, et al., Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2 (2015)

Brooun, et al., Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance (2016)

Antonysamy, et al., Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by X-ray crystallographic analysis of the EZH2-SET domain (2013)

Qi, et al., Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation (2012)

Nasveschuk, et al., Discovery and optimization of tetramethylpiperidinyl benzamides as inhibitors of EZH2 (2014)

U.S. Patent App. Pub. No. 2013/0040906

Brana et al., Reaction of N-(2-Pyridylmethyl)-3,5-dimethylbenzamide and N-(3-Pyridylmethyl)-3,5-dimethylbenzamide N-oxides with acetic anhydride (1982)

Diaz et al., Development and validation of reagents and assays for EZH2 peptide and nucleosome high-throughput screens (2012)

Brach et al., EZH2 inhibition by Tazemetostat results in altered dependency on B-cell activation signaling in DLBCL (2017)

Soumyanarayanan et al., Recently discovered EZH2 and EHMT2 (G9a) inhibitors (2016)

Miyaura et al., Palladium-catalyzed cross-coupling reactions of organoboron compounds (1995)

U.S. Patent App. Pub. No. 2014/0142083

File History for U.S. Patent 8,876,991

File History for U.S. Patent No. 9,157,017 (excerpt)

Petition for Inter Partes Review